Turing Pharmaceuticals
101 Avenue of Americas
9th Floor
New York
New York
10013
United States
Tel: 1-646-356-5577
Website: http://www.turingpharma.com/
56 articles with Turing Pharmaceuticals
-
Since reports surfaced that Martin Shkreli used a contraband cellular phone to conduct business from behind bars, the controversial biotech bad boy investor has not been heard from. And it may be because he is currently in solitary confinement.
-
The Federal Bureau of Prisons is investigating reports that Pharma Bro Martin Shkreli is using a contraband cellular telephone to continue to call the shots at his former company from prison.
-
Martin Shkreli may be behind bars, but that doesn’t mean he does not take a direct hand in running Turing Pharmaceuticals, the company that has been redubbed Phoenixus AG. The WSJ reports that Shkreli is still very much involved in the leadership of the company he founded.
-
A study published in the Annals of Internal Medicine highlights some of the problems that drug shortages bring to the healthcare system, including a rise in prices. The research, as highlighted by Business Insider, examined the prices of 917 drugs that were in shortage between 2015 and 2016.
-
Nirmal Mulye, chief executive officer of Missouri-based Nostrum Laboratories, is looking to take over Martin Shkreli’s mantle of being the poster-boy for drastic drug price increases.
-
More than a year after Maryland-based Sigma-Tau Pharmaceuticals changed its name to Leadiant Biosciences, the newly-dubbed company is now being associated with a much darker name – that of jailed biotech entrepreneur Martin Shkreli.
-
Martin Shkreli’s attorney and accomplice in committing wire fraud Evan Greebel has been sentenced to 18 months in prison. Greebel will spend far less time in prison than Shkreli, who was sentenced to seven years behind bars.
-
Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.
-
The Legacy of Martin Shkreli
3/9/2018
Martin Shkreli's actions were brash and often bizarre, but served as a catalyst for the pharma pricing debate. -
Biotech Founded By Pharma Bro Shkreli Escapes $43 Million Lawsuit
10/2/2017
U.S. District Judge Edgardo Ramos in Manhattan said Vyera was liable for the money under its contract with Impax, but did not have to pay it because Impax had violated the contract as well.
-
Pharma Bro Martin Shkreli Manages to Elect Five Pals to Turing's Board Before Trial
6/27/2017
-
Turing Receives $100 Million Offer on Drug That Made Martin Shkreli Famous
5/10/2017
-
Turing CEO and Shkreli Associate Exits Top Post, CSO Takes Over
4/24/2017
-
Turing Announces Toxoplasmosis Research Collaboration With Washington University in St. Louis
10/4/2016
-
Turing Announces Development Of New Drug Candidates For Toxoplasmosis
9/22/2016
-
The EpiPen Debacle Coupled With Theranos And Turing: Is This Industry Broken?
9/9/2016
-
Turing CCO Claims Execs Retaliated After Shkreli’s Friend and Co-Founder Resigned Due to Sexual Assault Allegations
8/25/2016
-
Life After Martin Shkreli — A Conversation With Turing's R&D Head
8/24/2016
-
Marina Biotech Acquires Late-Stage Program from Turing in $95 Million Deal
5/3/2016
-
Turing Provides Key Facts To Congressional Oversight Committee
2/4/2016